CP-320626
| Code | Size | Price |
|---|
| TAR-T31048-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31048-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31048-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CP-320626 is an effective inhibitor of glycogen phosphorylase A (LGPA) in the human liver and GPA in the human muscle. Can act synergistically with glucose. It is a possible target for the treatment of type 2 diabetes.
CAS:
186430-23-9
Formula:
C23H23ClFN3O3
Molecular Weight:
443.9
Purity:
0.98
SMILES:
OC1CCN(CC1)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1
References
1. Ma D, Wang J, Zhao Y, Lee WN, Xiao J, Go VL, Wang Q, Recker RR, Xiao GG. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas. 2012 Apr;41(3):397-408. doi: 10.1097/MPA.0b013e318236f022. PubMed PMID: 22158071; PubMed Central PMCID: PMC3306546.
2. Viz?n P, S?nchez-Tena S, Alcarraz-Viz?n G, Soler M, Messeguer R, Pujol MD, Lee WN, Cascante M. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis. 2009 Jun;30(6):946-52. doi: 10.1093/carcin/bgp083. Epub 2009 Apr 15. PubMed PMID: 19369582.
3. Gregus Z, N?meti B. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Toxicol Sci. 2007 Nov;100(1):44-53. Epub 2007 Aug 9. PubMed PMID: 17693424.
4. Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. Erratum in: Drug Metab Dispos. 2007 Jul;35(7):1246. PubMed PMID: 17194716.